Support for patients treated with growth hormone to reach their growth potential: addressing adherence barriers through personalised behavioural patient-support programmes

C. Moloney¹, S. Malik¹, J. Cancela², E. Koledova³
¹Atlantis Healthcare, London, UK; ²Medical Devices & Services, Ares Trading SA, an affiliate of Merck KGaA, Route de la Verriere 6, 1267 Coinins, Switzerland; ³Endocrinology, Global Medical, Safety and CMO, Merck KGaA, Darmstadt, Germany

INTRODUCTION

• Recombinant human growth hormone (r-hGH) treatment can optimize growth potential.¹
• However, optimal outcomes are not always achieved, owing to several reasons, including poor adherence.²
• This analysis sought to operationalize drivers of non-adherence in r-hGH patients using the evidence-based capability, opportunity and motivation (COM-B) behavioural framework as applied to adherence.³
• The COM-B framework can be used to help explain why patients do not engage in a recommended behaviour, such as adherence.

OBJECTIVES

• Identify key support needs across the r-hGH patient/caregiver pathways that drive optimal adherence and self-management.
• Utilize the COM-B framework to ensure a robust, evidence-based approach is taken to surface and identify these factors.
• Make recommendations for the design, content and techniques for a patient support program (PSP) for people treated with r-hGH.

METHODS

• A narrative review of the literature was conducted to determine drivers of non-adherence and key support needs in people prescribed r-hGH treatment.
• Academic papers dated 2000 to present day, focusing primarily on the needs of r-hGH patients and their caregivers, were sourced using key search terms.
• Findings were consolidated and summarized within the COM-B framework (Figure 1).

RESULTS

Adherence factors

• A multitude of factors emerged from the research as influential in determining adherence to r-hGH in patients with GH.
• These could be summarized in six key categories, and were relevant for either the patient and caregiver or the patient only (Figure 2).
• These six adherence factors were found to be influential at different stages of the patient/caregiver pathways and this was a consideration for the support recommendations (Figure 3).

Support design recommendations

• Based on these insights, three high-level support recommendations were made, to enhance PSPs by incorporating content and techniques that will facilitate adherence and support overall disease management.

1. Personalisation Questionnaire

2. Tailored reminders/support messages

3. PSP nurse coaching modules

• The personalization questionnaire, tailored reminder and support messages, and nurse-coaching modules will be piloted within the Saizen PSP programme.

REFERENCES


ACKNOWLEDGMENTS

Editorial assistance was provided by Steven Goodrick of inScience Communications, UK, and sponsored by Merck KGaA.

DISCLOSURES

Ekaterina Koledova is an employee of Merck KGaA, Darmstadt, Germany. Jorge Cancela is an employee of Ares Trading, an affiliate of Merck KGaA. Clare Moloney and Sumaira Malik are employees of Atlantis Healthcare, London, UK.